Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0O9UN
|
||||
| Former ID |
DNCL002043
|
||||
| Drug Name |
SAR231893
|
||||
| Indication | Asthma; Atopic dermatitis [ICD9: 493, 691.8, 692.9; ICD10:J45, L20-L30] | Phase 3 | [524747] | ||
| Company |
Sanofi
|
||||
| Target and Pathway | |||||
| Target(s) | Interleukin-4 receptor alpha chain | Target Info | Modulator | [524972], [532365] | |
| PANTHER Pathway | Interleukin signaling pathway | ||||
| Pathway Interaction Database | p73 transcription factor network | ||||
| IL4-mediated signaling events | |||||
| WikiPathways | Inflammatory Response Pathway | ||||
| IL-4 Signaling Pathway | |||||
| References | |||||
| Ref 524972 | ClinicalTrials.gov (NCT02277769) Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis. U.S. National Institutes of Health. | ||||
| Ref 532365 | Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med. 2013 Jun 27;368(26):2455-66. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.